The company is also excited to share the addition of key advisory positions, Jessica Kates (Rellevant Partners), Pamela Watkins (DuPont), and Rob Le Bras-Brown (HP Inc.).
Lieutenant General Thomas P. Bostick previously served as COO and president, Intrexon Bioengineering (NASDAQ: XON).
He serves as a senior advisor on biotechnology, infrastructure, sustainability, HR, and DEI.
Bostick serves on the boards of CSX (NASDAQ: CSX), and Perma-Fix (NASDAQ: PESI). He also serves on the board of HireVue, and Fidelity Investments' Equity and High-Income Fund board of Trustees.
He was the 53rd Chief of Engineers and Commanding General of the US Army Corps of Engineers.
Bostick serves on multiple non-profit boards. A member of the National Academy of Engineering, Bostick serves on several committees of the National Academy of Sciences focused on the environment and climate change.
He is a licensed professional engineer, a Forbes Contributor, and an Affiliated Scholar at Stanford University.
Bostick recently published his first book, Winning After Losing: Building Resilient Teams.
Allonnia is focused on a number of government related waste challenges including the treatment of PFAS contaminated sites and upcycling of rare earth elements.
Bostick's expertise mix is synergistic with Allonnia's priorities as they progress through continuing to build their federal and industrial strategy for development and deployment.
In addition to strengthening the board, Allonnia adds three industry veterans as advisors to strengthen day-to-day operations. The advisors bring both industry and functional expertise spanning Finance, People and Marketing.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government